A recent study presented at the Society of the 45th Annual Gynecological Oncology meeting in Tampa showed that a natural health product called AHCC (Active Hexose Correlated Compound) could eradicate the human papillomavirus virus (HPV) in mice. The researchers were expecting a reduction in the infection but were hugely surprised at complete eradication! They were in such disbelief at this amazing result that they repeated the experiment a second time and confirmed their findings!
HPV is the most common sexually transmitted virus in the United States and Canada. Up to 70% of sexually active adults will acquire HPV at some point in their lives. Human papillomavirus DNA has been detected in 99.7% of cervical cancer biopsies, suggesting a strong relationship with this type of cancer. According to the National Cancer Institute of the NIH:
1. HPV is responsible for 95% of cervical cancers, 85% of anal cancers, 50% of vaginal, vulvar & penile cancers and some throat/tongue ("oropharyngeal") cancers. By 2020, HPV is projected to cause more oropharyngeal cancers than cervical cancers in the United States.
2. At any point in time, 42.5% of women have genital HPV infections.
3. According to the NIH website "There is currently no medical treatment for HPV infections". There are vaccines for prevention which are very controversial but there is no treatment.
4. Women who are diagnosed are simply asked to come in for an annual PAP smear to detect cervical cancer.
One can imagine the impact of being able to eradicate the HPV infection with a natural health product.
The study was led by Dr. Judith A. Smith, of the University of Texas Health Science Center Medical School in Houston. In the first part of the study, cervical cancer cells were treated with AHCC and incubated for 72 hours. The cancer cells were killed off with just one dose of AHCC. The study was then repeated in two mouse models, one HPV positive and the other an HPV negative control. In these models the cancer cells were transplanted into mice where they would normally develop into tumours. Dr. Smith then repeated the study to confirm findings and to determine the mechanism by which AHCC eradicates the HPV virus; this was done by looking at various immune markers.
The data suggests that AHCC can eliminate HPV infections and may have a role in the prevention of HPV-related cancers as well.
“The results of this study were very encouraging,” said Dr. Smith, Associate Professor at the Medical School. “This study, initiated in 2008, shows that by itself AHCC has the potential to treat the HPV infection,” she said. Smith’s previous study evaluated AHCC integration with common chemotherapy agents used for the treatment of ovarian cancer, to screen for potential drug interactions and improvement in activity. A pilot study in HPV+ women is also underway at University of Houston.
Human and animal studies have shown that AHCC increases the number and/or activity of Natural Killer (NK) and other immune cells which enable the body to effectively respond to infections and block the development of cancers. “AHCC is a common, well tolerated nutritional supplement that has been used for decades in Japan, I am very excited to be pursuing a nutritional approach to trying to find a treatment for HPV infections,” said Dr. Smith, whose research is on drug development for gynecologic cancers.
Smith’s previous study evaluated AHCC with common chemotherapy agents used for the treatment of ovarian cancer, to screen for potential drug interactions and improvement in activity. “We had previously demonstrated an antiretroviral regimen that successfully eradicated the HPV infection but wanted to develop a more benign protocol, since these medications have a number of side effects,” Dr. Smith continued.
AHCC is a natural immune-modulating compound derived from a unique fraction of specially-cultured medicinal mushroom mycelia. It works by using the body’s own immune system to help fight disease. Supported by more than 20 published clinical human studies and over 100 animal studies, AHCC has been investigated at prestigious institutions including Yale Medical School, Columbia Presbyterian Hospital, Brigham and Women’s Hospital and MD Anderson Cancer Center, and various universities in Japan. AHCC has been clinically shown to help patients with cancer, hepatitis, liver disease, as well as viral and bacterial infections. AHCC has been used in over 1000 medical clinics and hospitals worldwide.
AHCC is also widely used by healthy individuals seeking to maintain peak immune function. A recent human clinical study has shown that AHCC taken in conjunction with the flu shot increased anti-body titers more than the vaccine alone in healthy adults. AOR now offers the highest potency and most cost-effective AHCC on the market.
This recent study in mice shows that AHCC may be able to help millions of women affected by human papilloma virus related conditions. Click here for more information on the immune boosting benefits of AHCC.
- Clinical Perspectives on the Role of the Human Papillomavirus Vaccine in the Prevention of Cancer, Justin M. Julius et-al Pharmacotherapy. 2011;31(3):280-297